NCT06636071View on ClinicalTrials.gov

Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 25, 2024

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Osteogenesis Imperfecta
Interventions
BIOLOGICAL

setrusumab

A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion

Trial Locations (3)

Unknown

Osaka Metropolitan University Hospital, Osaka

Osaka University Hospital, Osaka

Keio University Hospital, Tokyo

All Listed Sponsors
lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT06636071 - Setrusumab in Pediatric Japanese Subjects With Osteogenesis Imperfecta | Biotech Hunter | Biotech Hunter